Answers are grounded in this paper and cite their sources.
This consensus statement provides practical recommendations for managing lipid-lowering therapy, highlighting inclisiran, to achieve LDL-C targets and prevent recurrence in stroke/TIA patients.
BACKGROUND: Stroke represents a major public health challenge in Spain, with approximately 120 000 cases per year and a significant impact on mortality, disability, and dependency. Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable causal factor in preventing vascular recurrences. This consensus statement aims to provide a comprehensive framework for the practical management of lipid-lowering therapy in patients with stroke or transient ischaemic attack (TIA). METHODS: A panel of experts in neurology, specialised in the management of patients with stroke/TIA, participated in 3 sessions to review the latest evidence. Subsequently, they reached consensus on practical recommendations for the management of lipid-lowering therapy based on data from clinical trials, meta-analyses, and current clinical guidelines. CONCLUSIONS: Achieving the therapeutic targets for LDL-C is essential to prevent recurrence in patients with stroke/TIA. To ensure comprehensive management of LDL-C in patients with stroke/TIA, the application of intensive therapeutic strategies, individualised approaches, and robust continuity of care are recommended to optimise secondary prevention. Treatment planning at discharge, neurologist-led risk factor control, and coordinated continuity of care between hospital and primary care settings are essential factors determining long-term outcomes. Inclisiran has emerged as a new key therapy to improve lipid control and treatment adherence in these patients, in alignment with national and international recommendations for achieving therapeutic targets and reducing the burden of vascular disease. Optimal implementation of this therapeutic approach may substantially contribute to improving the prognosis of patients with stroke/TIA.
No takes yet. Share an insight, caveat, or question.
Freijo-Guerrero et al. (2026) conducted a review in Stroke or transient ischaemic attack (TIA). Lipid-lowering therapy (including inclisiran) was evaluated. A consensus panel of neurology experts recommends intensive, individualized lipid-lowering therapy, including inclisiran, to achieve LDL-C targets and prevent vascular recurrences in stroke/TIA patients.
Synapse has enriched 10 related papers. Consider them for comparative context: